Key facts
- This page summarizes Matthew W. Strobeck's Form 4 filing for Accelerate Diagnostics, Inc (AXDX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 25 Jan 2024, 16:12.
Matthew W. Strobeck - 23 Jan 2024 Form 4 Insider Report for Accelerate Diagnostics, Inc (AXDX)
- Reporting relationship
- Director
- Issuer ticker
- AXDX
- Reported as of
- 23 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 25 Jan 2024, 16:12:05 UTC
- Prior SEC filing
- 03 Jan 2024
- Next SEC filing
- 09 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Patience, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Matthew W. Strobeck filed Form 4 for Accelerate Diagnostics, Inc (AXDX) on 25 Jan 2024.
Change
- Previous filing in this sequence was filed on 03 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AXDX
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +100,000
- Change %
- +484%
- Price
- Shares after
- 120,682
- Date
- 23 Jan 2024
- Ownership
- By Birchview Fund, LLC
- Footnotes
- F1, F2
AXDX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 202,556
- Date
- 23 Jan 2024
- Ownership
- Direct
AXDX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,000
- Date
- 23 Jan 2024
- Ownership
- As UGMA Custodian for minor children
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AXDX
transaction
Derivative
Common Stock Warrants (right to buy)
Purchase
- Transaction value
- Shares
- +100,000
- Change %
- Price
- Shares after
- 100,000
- Date
- 23 Jan 2024
- Ownership
- By Birchview Fund, LLC
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $1.65
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The reported securities are included within 100,000 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit in an underwritten public offering. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock.
Footnote F2
The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
SEC remarks
On July 11, 2023, the issuer effected a reverse stock split of its common stock at a ratio of 1-for-10 (the "Reverse Stock Split"). As a result of the Reverse Stock Split, proportionate adjustments were made to the number of shares of the issuer's common stock underlying its outstanding equity awards, warrants and convertible notes, as well as the exercise or conversion price, as applicable. The amounts reported herein (and to be reported in subsequent reports) have been adjusted to reflect the Reverse Stock Split.